Royalty Pharma (<strongNasdaq: RPRX), a leading biopharmaceutical royalty buyer, successfully priced a $2 billion offering of senior unsecured notes. The offering comprises three tranches: $600 million in 4.450% notes maturing in 2031; $900 million in 5.200% notes maturing in 2035; and $500 million in 5.950% notes maturing in 2055.
These notes will be guaranteed by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The company anticipates the offering will close on September 16, 2025, pending customary closing conditions.
Royalty Pharma plans to allocate the net proceeds from the note offering to general corporate purposes. Several major investment banks acted as joint lead book-running managers and representatives of the underwriters. These include BofA Securities, Goldman Sachs & Co. LLC, J.P. Morgan, Morgan Stanley, and TD Securities. A group of additional firms served as co-managers for the offering.
The notes are being offered under an effective shelf registration statement filed with the Securities and Exchange Commission (SEC). Interested parties can access the preliminary prospectus supplement and accompanying prospectus through the SEC website or by contacting the designated underwriters.
Established in 1996, Royalty Pharma is a significant investor in biopharmaceutical innovation. The company partners with various entities, ranging from academic institutions to large pharmaceutical firms, acquiring royalties from both commercial and developmental products. This strategy allows Royalty Pharma to generate income from a diverse portfolio of leading therapies.
The company’s portfolio encompasses royalties on over 35 commercial products and 17 products under development. These products span various therapeutic areas and are marketed by leading pharmaceutical companies such as Vertex, GSK, Roche, Johnson & Johnson, Biogen, AbbVie, Astellas, Pfizer, Novartis, and Gilead.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the notes. The offering is subject to applicable laws and regulations. Investors should carefully review the offering documents before making any investment decisions. The company included a statement addressing forward-looking information, cautioning against undue reliance on predictions of future performance.
Related
